Whether or not this new insight will aid in the development of non-covalent allosteric therapeutics that specifically target the more common G12V and G12D K-Ras amino acid substitutions that are associated with cancers of the pancreas and large intestine remains to be seen. Here, KRAS is linked to pancreatic neoplasm.